News & Updates

Beyond 1 year, the humanized monoclonal antibody mepolizumab maintained real-world efficacy and safety in patients with severe eosinophilic asthma in the REALITI-A cohort study, reports an expert at ERS 2021.

Adding cyclophosphamide to glucocorticoid treatment in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) was associated with a numerically increased risk of mortality, according to results of the phase III EXAFIP trial.

Investigations into the role of small aerosol particles in COVID-19 transmission suggest that SARS-CoV-2 may be an airborne hazard. A recent medRxiv preprint study from Singapore adds to this body of evidence.

What used to be a place that holds a perception of relative safety and minimal health risk to its occupants, the office now appears to be a place that is inching its way towards the other side of the respiratory health spectrum, with office-related occupational asthma on the rise, according to findings from a UK cross-sectional study presented at ERS 2021.

Use of tofacitinib for rheumatoid arthritis (RA) may lead to reactivation of hepatitis B virus (HBV), especially among hepatitis B surface antigen-positive (HBsAg+) and HBsAg-negative/hepatitis B core antibody-positive (HBsAg–/HBcAb+) patients, according to a study from Taiwan.